Point Mutations in Furazolidone and Rifampicin Resistance Genes in Strains from Colombia.

The eradication of is a valid strategy for preventing gastric cancer; however, the therapeutic failure of first-line treatments in Colombia is associated with high resistance to metronidazole and amoxicillin. This study explored alternative antibiotics and analyzed point mutations in resistance genes to furazolidone and rifampicin in order to include them in rescue therapy regimens. A total of 239 complete genomes of Colombian strains were compared to that of the ATCC 26695 strain to identify mutations in the and genes for rifampicin and furazolidinone resistance, respectively.